Abstract: A method of annotating biomolecular sequences The method comprises (a) computationally clustering the biomolecular sequences according to a progressive homology range, to thereby generate a plurality of clusters each being of a predetermined homology of the homology range; and (b) assigning at least one ontology to each cluster of the plurality of clusters, the at least one ontology being: (i) derived from an annotation preassociated with at least one biomolecular sequence of each cluster; and/or (ii) generated from analysis of the at least onic biomolecular sequence of each cluster thereby annotating biomolecular sequences.

Abstract: A method of annotating biomolecular sequences. The method comprises (a) computationally clustering the biomolecular sequences according to a progressive homology range, to thereby generate a plurality of clusters each being of a predetermined homology of the homology range; and (b) assigning at least one ontology to each cluster of the plurality of clusters, the at least one ontology being: (i) derived from an annotation preassociated with at least one biomolecular sequence of each cluster; and/or (ii) generated from analysis of the at least one biomolecular sequence of each cluster thereby annotating biomolecular sequences.

Abstract: An isolated nucleic acid sequence depicted in SEQ ID NO:6 is an alternative splice variant of human kallikrien-2 gene (KLK-2). An expression vector containing the splice variant and a host cell transfected by the expression vector are provided. The nucleic acid is useful for determining the level of nucleic acid sequences of human kallikrien variants in a biological sample.

Abstract: The invention concerns novel nucleic acid sequences and amino acid sequences obtained by alternative splicing, expression vectors, host cell and pharmaceutical compositions comprising said sequences.

Abstract: The invention concerns novel nucleic acid sequences, amino acid sequences coded thereby and method of detection using the above. The novel nucleic acid sequences are naturally occurring splice variants of a prostate specific antigen sequence (PSA) or of the KLK-2 gene.

Abstract: The present invention provides oligonucleotide libraries capable of detecting RNA transcripts and RNA splice variants which populate a transcriptome and which are transcribed from genes or transcription units that populate the corresponding genome. The present invention also provides oligonucleotide arrays generated from the oligonucleotide libraries and methods of using the oligonucleotide libraries in various oligonucleotide detection systems and expression profiling studies. Antisense molecules and double-stranded interfering RNAs, which are types of oligonucleotides, based on the oligonucleotides disclosed herein also are provided.

Abstract: The invention concerns novel nucleic acid sequences and amino acid sequences of a novel variant of vascular endothelial growth factor (VEGF). The invention further concerns expression vectors and host cells containing said sequences as well as pharmaceutical compositions and detection methods using said sequences.

Abstract: The invention concerns novel nucleic acid and amino acid sequences which are homologues to steroidogenic acute regulatory protein. The invention further concerns expression vectors comprising these sequences and host cells transfected with the vectors. The invention further concerns pharmaceutical compositions.

Abstract: The present invention teaches novel Eps15 homology (EH) domain containing proteins, polynucleotide sequences encoding the novel EH domain containing proteins, oligonucleotides and oligonucleotide analogs derived from the polynucleotide sequences, a display library displaying short peptides derived from the EH domain containing proteins, antibodies recognizing the EH domain containing proteins, peptides or peptide analogs derived from the EH domain containing proteins, and pharmaceutical compositions and methods of employing the peptides or peptide analogs, the oligonucleotides and oligonucleotide analogs, and/or the polynucleotide sequences to up-regulate or down-regulate clathrin coated pit mediated endocytosis and thereby insulin growth factor 1 receptor (IGF1 receptor) signaling.

Abstract: The invention concerns novel nucleic acid sequences and amino acid sequences of a novel variant of vascular endothelial growth factor (VEGF). The invention further concerns expression vectors and host cells containing said sequences as well as pharmaceutical compositions and detection methods using said sequences.

Abstract: The present invention teaches novel Eps15 homology (EH) domain containing proteins, polynucleotide sequences encoding the novel EH domain containing proteins, oligonucleotides and oligonucleotide analogs derived from the polynucleotide sequences, a display library displaying short peptides derived from the EH domain containing proteins, antibodies recognizing the EH domain containing proteins, peptides or peptide analogs derived from the EH domain containing proteins, and pharmaceutical compositions and methods of employing the peptides or peptide analogs, the oligonucleotides and oligonucleotide analogs, and/or the polynucleotide sequences to up-regulate or down-regulate clathrin coated pit mediated endocytosis and thereby insulin growth factor 1 receptor (IGF1 receptor) signaling.

Abstract: The invention concerns novel nucleic acid sequences and amino acid sequences of a novel variant of vascular endothelial growth factor (VEGF). The invention further concerns expression vectors and host cells containing said sequences as well as pharmaceutical compositions and detection methods using said sequences.

Abstract: The invention concerns novel nucleic acid sequences, amino acid sequences coded thereby and method of detection using the above. The novel nucleic acid sequences are naturally occurring splice variants of a prostate specific antigen sequence (PSA) or of the KLK-2 gene.

Abstract: The present invention provides nucleic acid sequences, of an alternative splicing variant of metabotropic glutamate receptor (mGluR). The invention also provides amino acid sequences coded by the isolated nucleic sequences purified antibodies, which binds specifically to the amino acid sequences, and expression vectors comprising any one of the nucleic acid sequences. The invention also provides pharmaceutical compositions comprising as an active ingredient the expression vector or an amino acid sequence.